Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05255237

Acronym

Enrollment

315

Registered

2022-02-24

Start date

2022-03-25

Completion date

2024-06-28

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Brief summary

This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020) study. After completion of ZGJAK018 study, the study will be directly extend with an open-label design.

Interventions

DRUGJaktinib

75mg BID

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Subjects voluntarily sign the informed consent form. * Patients who participated in ZGJAK018.

Exclusion criteria

* Subjects who are unsuitable to the trial, as identified by the investigator.

Design outcomes

Primary

Measure	Time frame	Description
Number of subjects reporting treatment-emergent adverse events	Baseline through week 24	Patients with treatment-emergent adverse events/all patients \*100%

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026